

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
				Application Number	10/619,454-Conf. #7700
				Filing Date	July 16, 2003
				First Named Inventor	Cheryl Fitzer-Altas
				Art Unit	1649
				Examiner Name	S. H. Standley
Sheet	1	of	4	Attorney Docket Number	20555/1203432-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (#known)			
/S.S./	AA*	US-4,582,788	04-15-1986	Erlich	
/S.S./	AB*	US-4,683,202-B1	07/1987	Mullis	
/S.S./	AC*	US-20040043935-A1	03-04-2004	Frangione et al.	
/S.S./	AD*	US-20030166558-A1	09-04-2003	Frangione et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number-Kind Code ³ (#known)			
/S.S./	BA	WO-99/27944	06-10-1999	Athena Neurosciences Inc et al.	
/S.S./	BB	WO-00/72876	12-07-2000	Neuralab Ltd et al.	
/S.S./	BC	WO-0190182	11-29-2001	Univ New York et al.	
/S.S./	BD	WO-03/045128	06-05-2003	Univ New York et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/S.S./	CA	Bauer, J. et al. "Inflammation in the nervous system: the human perspective". 2001 Glia 36: 235-243.			
/S.S./	CB	Blen, C.G., et al. "Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis." Ann Neurol 2002 March; 51(3):311-8			
/S.S./	CC	Blasko I, et al., "B TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs." FASEB J 1999 January; 13(1):63-8			
/S.S./	CD	Buscighio, J. et al. "Generation of beta-amyloid in the secretory pathway in neuronal and normeurnonal cells." (1993) Proc Natl Acad Sci USA 90:2092-2096			
/S.S./	CE	Buus S, et al., "Receptor-ligand interactions measured by an improved spun column chromatography technique. A high efficiency and high throughput size separation method." Biochim Biophys Acta. Apr. 13, 1995; 1243(3):453-60.			
/S.S./	CF	Check, E. "Nerve inflammation halts trial for Alzheimer's drug." Nature. Jan. 31, 2002;415(6871):462.			
/S.S./	CG	Gay, F. W. et al. "The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion."			

Examiner Signature 00938852.doc	/Steven Standley/	Date Considered	09/30/2007
------------------------------------	-------------------	-----------------	------------

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/619,454-Conf. #7700
				Filing Date	July 16, 2003
				First Named Inventor	Cheryl Fitzer-Atlas
				Art Unit	1649
				Examiner Name	S. H. Standley
Sheet	2	of	4	Attorney Docket Number	20555/1203432-US1

		Brain. 1997 August;120 (Pt 8):1461-83.	
/S.S./	CH	Geddes, J. W. et al, "N-terminus truncated beta-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease." <i>Neurobiol Aging</i> . 1999 20(1):75-9	
/S.S./	CI	Glenner, G. G. and Wong, C. W. "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein." (1984) <i>Biochem Biophys Res Commun</i> 120:885-890.	
/S.S./	CJ	Griffin D E, et al. "The immune response in viral encephalitis." <i>Semin Immunol</i> 1992 April; 4(2):111-9.	
/S.S./	CK	Haass, C. et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism." (1992) <i>Nature</i> 359:322-325	
/S.S./	CL	Haas, C. et al, "Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid b-protein precursor." <i>J Biol. Chem.</i> 269, 17741-17748.	
/S.S./	CM	Higgins, L.S. et al, "p3 b amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." <i>Am J. Pathol</i> 149, 585-598.	
/S.S./	CN	Janus, C. et al. "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease." 2000 <i>Nature</i> 408, 979-982.	
/S.S./	CO	Joachim, C. L. et al. "Protein chemical and immunocytochemical studies of meningo-vascular beta-amyloid protein in Alzheimer's disease and normal aging." (1988) <i>Brain Res</i> 474:100-111	
/S.S./	CP	Kang, J. et al. "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor." <i>Nature</i> . Feb. 19-25, 1987; 325(6106):733-6	
/S.S./	CQ	Kimura, T. & Griffin, D. E., "The role of CD8(+) T cells and major histocompatibility complex class I expression in the central nervous system of mice infected with neurovirulent Sindbis virus." <i>J Virol</i> 2000 July; 74(13):6117-25	
/S.S./	CR	Lalowski M et al., "The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid." 1996 <i>J Biol Chem</i> 271(52):33623-31	
/S.S./	CS	Lamer, A. J. "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." <i>Neurobiol. Of Aging</i> 20, 65-69.	
/S.S./	CT	Marx, F., "Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production." <i>Exp Gerontol</i> 1999 September; 34(6):783-95	
/S.S./	CU	Morgan, D., et al. "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease." 2000 <i>Nature</i> 408, 982-985.	
/S.S./	CV	Mori, H. et al. "Mass spectrometry of purified amyloid beta protein in Alzheimer's disease." (1992) <i>J Biol Chem</i> 267:17082-17806.	
/S.S./	CW	Naslund, J. et al. "Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging." (1994) <i>Proc Natl Acad Sci USA</i> 91:8378-8382.	
/S.S./	CX	Neumann, H. et al. "Major histocompatibility complex (MIC) class I gene expression in single neurons of the central nervous system: differential regulation by Interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha." 1997 <i>J Exp Med</i> 185: 305-316.	

Examiner Signature 00939852.doc	/Steven Standley/	Date Considered	09/30/2007
------------------------------------	-------------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/619,454-Conf. #7700
				Filing Date	July 16, 2003
				First Named Inventor	Cheryl Fitzer-Attas
				Art Unit	1649
				Examiner Name	S. H. Standley
Sheet	3	of	4	Attorney Docket Number	20555/1203432-US1

/S.S./	CY	Oldstone, M. B. & Southern, P. J., "Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model." 1993 J Neuroimmunol 46:25-31	
/S.S./	CZ	Ostergaard Pedersen L., et al, "Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds." Eur J. Immunol. 2001 October; 31(10):2988-96	
/S.S./	CA1	Parker, K. C., et al, "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains." J. Immunol. 152:163.	
/S.S./	CB1	Plake, C.J., et al, "Amino-terminal deletions enhance aggregation of P-amyloid peptides in vitro". J Biol Chem 270, 23895-8.	
/S.S./	CC1	Prelli, F. et al. "Differences between vascular and plaque core amyloid in Alzheimer's disease." (1988) J Neurochem 51:648-651	
/S.S./	CD1	Rammensee, Hans-Georg, et al. "SYFPEITHI: database for MHC ligands and peptide motifs." Immunogenetics (1999) 50: 213-219 (access via: http://www.uni-tuebingen.de/unil/kxl/)	
/S.S./	CE1	Reche, P.A., et al. "Prediction of MHC Class I Binding Peptides Using Profile Motifs." Human Immunology 63, 701-709 (2002).	
/S.S./	CF1	Roher, A. E. et al. "beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease." (1993) Proc Natl Acad Sci USA 90:10836-10840	
/S.S./	CG1	Schenk, D. et al. "Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse." 1999 Nature 400, 173-177.	
/S.S./	CH1	Seubert, P. et al. "Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids." (1992) Nature 359:325-327	
/S.S./	CI1	Stuiniolo, T., et al., "Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices." Nat. Biotechnol. 17. 555-561(1999)	
/S.S./	CJ1	Tekleian, T.L., "Commentary: Abeta N-Terminal Isoforms: Critical contributors in the course of AD pathophysiology." J Alzheimers Dis. 2001 April; 3(2):241-248.	
/S.S./	CK1	Traugott, U. "Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development." 1987 J Neuropathol 16: 283-302.	
/S.S./	CL1	Vass, K. & Lassmann, H. "Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system." 1990 Am J. Pathol 137: 789-800.	
/S.S./	CM1	Scharf et al., "Direct Cloning and Sequence Analysis of Enzymatically Amplified Genomic Sequences." Science, Vol. 233, No. 4768, pp. 1076-1078	
/S.S./	CN1	Cox et al., "HLA-DR Typing "at the DNA Level": RFLPs and Subtypes Detected with a DR β cDNA Probe." Am. J. Hum. Gen., 43:954-963, 1988	
/S.S./	CO1	Tiercy, Jean-Marie, et al., "Identification and Distribution of Three Serologically Undetected Alleles of HLA-DR by Oligonucleotide-DNA Typing Analysis." Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 198-202, 1988	
/S.S./	CP1	Tiercy, Jean-Marie, et al., "DNA Typing of DRw6 Subtypes: Correlation with DRB1 and DRB3 Allelic Sequences by Hybridization with Oligonucleotide Probes." Hum. Immunol. 24, pp. 1-14 (1989)	
/S.S./	CQ1	Salki, Randall K., et al., "Analysis of Enzymatically Amplified β -globin and HLA-DQ α DNA with	

Examiner Signature 00939852.doc	/Steven Standley/	Date Considered	09/30/2007
------------------------------------	-------------------	-----------------	------------

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/619,454-Conf. #7700
				Filing Date	July 16, 2003
				First Named Inventor	Cheryl Fitzer-Altas
				Art Unit	1649
				Examiner Name	S. H. Standley
Sheet	4	of	4	Attorney Docket Number	20555/1203432-US1

		Allele-Specific Oligonucleotide Probes." Nature, Vol. 324, pp. 163-166, 1986	
/S.S./	CR1	Bugawan, Theodorica L., et al., "Analysis of HLA-DP Allelic Sequence Polymorphism Using the In Vitro Enzymatic NDA Amplification of DP- α and DP- β Loci." J. Immunol., Vol. 141, No. 12, pp. 4024-4030, 1988	
/S.S./	CS1	Gyllensten, Ulf B., et al., "Generation of Single-Stranded DNA by the Polymerase Chain Reaction and its Application to Direct Sequencing of the HLA-DQA Locus." Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 7652-7656, 1988	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 00939852.doc	/Steven Standley/	Date Considered	09/30/2007
------------------------------------	-------------------	-----------------	------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10619454	
	Filing Date		2003-07-16	
	First Named Inventor		Cheryl Fitzer-Attas	
	Art Unit		1649	
	Examiner Name		S. H. Standley	
	Attorney Docket Number		20555/1203432-US1	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1 /S.S./	1	01/90182	WO		2001-11-29	Univ New York et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS						Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10619454
	Filing Date	2003-07-16
	First Named Inventor	Cheryl Fitzer-Attas
	Art Unit	1649
	Examiner Name	S. H. Standley
	Attorney Docket Number	20555/1203432-US1

/S.S./	1	SIGURDSSON, et al. "Immunization With a Nontoxic/Nonfibrillar Amyloid-Beta-Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice" American Journal of Pathology, Vol. 159, No. 2, August 2001, pp. 439-447	<input type="checkbox"/>
/S.S./	2	PALLITTO, et al. "Recognition Sequence Design for Peptidyl Modulators of Beta-Amyloid Aggregation and Toxicity" Biochemistry, Vol. 38, No. 12, March 23, 1999, pp. 3570-3578.	<input type="checkbox"/>
/S.S./	3	DICKEY, et al. "Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated Beta-Amyloid 1-42 Peptide" DNA and Cell Biology, Vol. 20, No. 11, November 2001, pp. 723-729	<input type="checkbox"/>
/S.S./	4	SCHONBACH, et al. "Large-Scale Computational Identification of HIV T-Cell Epitopes" Immunology and Cell Biology, Vol. 80, No. 3, June 2002, pp. 300-306	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Steven Standley/	Date Considered	09/30/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10619454
Filing Date	2003-07-16
First Named Inventor	Cheryl Fitzer-Attas
Art Unit	1649
Examiner Name	S. H. Standley
Attorney Docket Number	20555/1203432-US1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	2007-09-10
Name/Print	S. Peter Ludwig	Registration Number	25351

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.